PharmaMar: Neoplasms trials

The registry lists 12 Neoplasms studies with PharmaMar as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 8Phase 2 4Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid TumorsCompletedNCT02533674Phase 1Results posted
• Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid TumorsCompletedNCT02454972Phase 2Results posted
• Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid TumorsCompletedNCT02451007Phase 2Results posted
• Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of ChemotherapyCompletedNCT01222767Phase 2Results posted
• Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)Active, not recruitingNCT06088290Phase 3
• PM14 Administered Intravenously to Patients With Advanced Solid TumorsCompletedNCT05076396Phase 1
• Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsCompletedNCT02611024Phase 1/2
• Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid TumorsCompletedNCT01980667Phase 1
• Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid TumorsCompletedNCT01970553Phase 1
• Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid TumorsCompletedNCT00884845Phase 1
• Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid TumorsCompletedNCT00877474Phase 1
• A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid TumorsTerminatedNCT00404521Phase 1